Amjevita

Pharma

With biosim sales up 16%, Amgen expects another boost in 2025

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion by the end of the decade.

Kevin Dunleavy Feb 5, 2025 11:28am

FDA approves Amgen's interchangeable biosimilar of J&J's Stelara

Nov 1, 2023 10:20am

Boehringer rolls out unbranded Humira biosim at steep discount

Oct 4, 2023 10:53am

Biosimilars make inroads into Humira sales; docs still cautious

Sep 19, 2023 9:35am

Amgen's hyped Humira biosimilar generates just $19M in Q2 sales

Aug 4, 2023 8:35am

Amgen launched Humira biosim to its own detriment

Apr 28, 2023 11:05am